GH1 and hereditary endocrine growth disease: The GH trials led to a worldwide shift towards the centralization of care for children with growth disorders, including those with TS to pediatric endocrinologists working within university hospitals and national centers such as GP-GRC in Sweden, responsible for both clinical care and research.